The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma

Trial Profile

The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Asunercept (Primary)
  • Indications Glioblastoma
  • Focus Biomarker; Therapeutic Use
  • Sponsors CANbridge Life Sciences
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
    • 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
    • 18 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top